EXPRESSION AND CHARACTERIZATION OF FINGER PROTEASE (FP) - A MUTANT TISSUE-TYPE PLASMINOGEN-ACTIVATOR (T-PA) WITH IMPROVED PHARMACOKINETICS

被引:6
作者
TRILL, JJ
FONG, KL
SHEBUSKI, RJ
MCDEVITT, P
ROSA, MD
JOHANSON, K
WILLIAMS, D
BOYLE, KE
SELLERS, TS
REFF, ME
机构
[1] SMITH KLINE BEECHAM PHARMACEUT,DEPT PROT BIOCHEM,KING OF PRUSSIA,PA 19406
[2] SMITH KLINE BEECHAM PHARMACEUT,DEPT PHARMACOL,KING OF PRUSSIA,PA 19406
[3] SMITH KLINE BEECHAM PHARMACEUT,DEPT DRUG METAB,KING OF PRUSSIA,PA 19406
[4] SMITH KLINE BEECHAM PHARMACEUT,DEPT EXPTL PATHOL,KING OF PRUSSIA,PA 19406
[5] BIOGEN RES CORP,CAMBRIDGE,MA 02142
关键词
Fibrinolytics; Pharmacokinetics; Tissue plasminogen activator;
D O I
10.1016/S0268-9499(05)80044-X
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
We have constructed, expressed and purified a novel thrombolytic, finger protease (FP), composed of only the finger and serine protease domains of t-PA. This molecule, when compared to t-PA, has improved pharmacokinetics (slower plasma clearance and a longer half-life) in both the rat and rabbit. It is half as potent as t-PA in a rabbit model of peripheral arterial thrombosis. At efficacious doses, FP produced larger changes in haemostatic parameters than those produced by t-PA. In vitro studies of the purified protein showed weak fibrin binding, and low specific activity of FP in both the S-2251 and human clot lysis assays. The behavior of this molecule suggests that novel fibrinolytics with improved pharmacokinetics and equivalent in vitro activity to t-PA will be more potent in vivo. © 1990 Longman Group UK Ltd.
引用
收藏
页码:131 / 140
页数:10
相关论文
共 32 条
[1]  
BROWNE MJ, 1988, J BIOL CHEM, V263, P1599
[2]  
COLLEN D, 1980, THROMB HAEMOSTASIS, V43, P77
[3]  
COLLEN D, 1984, J PHARMACOL EXP THER, V231, P146
[4]   DHFR COAMPLIFICATION OF T-PA IN DHFR+ BOVINE ENDOTHELIAL-CELLS - INVITRO CHARACTERIZATION OF THE PURIFIED SERINE PROTEASE [J].
CONNORS, RW ;
SWEET, RW ;
NOVERAL, JP ;
PFARR, DS ;
TRILL, JJ ;
SHEBUSKI, RJ ;
BERKOWITZ, BA ;
WILLIAMS, D ;
FRANKLIN, S ;
REFF, ME .
DNA-A JOURNAL OF MOLECULAR & CELLULAR BIOLOGY, 1988, 7 (09) :651-661
[5]  
DEVRIES C, 1989, J BIOL CHEM, V264, P12604
[6]  
EHRLICH H J, 1987, Fibrinolysis, V1, P75, DOI 10.1016/0268-9499(87)90013-0
[7]   VARIANTS OF HUMAN TISSUE-TYPE PLASMINOGEN-ACTIVATOR THAT LACK SPECIFIC STRUCTURAL DOMAINS OF THE HEAVY-CHAIN [J].
GETHING, MJ ;
ADLER, B ;
BOOSE, JA ;
GERARD, RD ;
MADISON, EL ;
MCGOOKEY, D ;
MEIDELL, RS ;
ROMAN, LM ;
SAMBROOK, J .
EMBO JOURNAL, 1988, 7 (09) :2731-2740
[8]  
Gibaldi M., 1982, PHARMACOKINETICS, Vsecond
[10]   THE ROUS-SARCOMA VIRUS LONG TERMINAL REPEAT IS A STRONG PROMOTER WHEN INTRODUCED INTO A VARIETY OF EUKARYOTIC CELLS BY DNA-MEDIATED TRANSFECTION [J].
GORMAN, CM ;
MERLINO, GT ;
WILLINGHAM, MC ;
PASTAN, I ;
HOWARD, BH .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA-BIOLOGICAL SCIENCES, 1982, 79 (22) :6777-6781